RNAi therapy hits cholesterol endpoints in two more Phase IIIs ahead of Medicines Co.'s submission

With readouts now in from three pivotal trials, Medicines Co. could seek a claim of reduced CV risk in its planned regulatory submissions of inclisiran for LDL-C reduction.

The announcement of results from the latest two trials drove shares of The Medicines Co. (NASDAQ:MDCO) up $2.61 to $49.75 on Wednesday, ending the day with a market cap of about $4 billion after touching an intraday 52-week high of $51.93...